Given the extensive safety data for IGF-1 in children with short stature due to primary IGF-1 deficiency, IGF-1 is an attractive candidate for controlled clinical trials in SHANK3-deficiency and in ASD. Here, SHANK3 is linked to hyperinsulinemic hypoglycemia, familial, 4.